ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

paliperidone

Also written as “Paliperidone ER”, “Paliperidone” and “Paliperidone palmitate”.

Its studies are mostly in Schizophrenia · Psychotic Disorders · Bipolar Disorder · Psychomotor Agitation, led by 4 companies.

Drug pagePaliperidone: every studyAll 136 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 30, 2007106 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnsonits history only1000 open or runningphase 4since Aug 30, 2007Nov 19, 2003none ahead
Luye Pharma Group30 open or runningphase 1since May 8, 2020May 8, 2020none ahead
CSPC Pharmaceutical Groupits history only21 open or runningno phasesince Sep 30, 2025Sep 30, 2025Dec 31, 2026NCT07493551
Pharmathenits history only10 open or runningphase 2since Jan 26, 2018Jan 26, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Luye Pharma Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 8, 2020First study: phase 1 study in Schizophrenia PatientsFirst studyNCT04572685 · 36 enrolled · United States
  2. Apr 27, 2021Phase 1 study in SchizophreniaNCT04922593 · 281 enrolled · United States
  3. Dec 6, 2021Phase 1 study in SchizophreniaNCT05321602 · 89 enrolled · United States

TargetBeta

DRD2 →HTR2A →read by rule
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
lurasidoneruleSumitomo Pharmaphase 452
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 3 Luye Pharma Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05321602Schizophrenia · United States1CompletedSep 23, 202289
NCT04922593Schizophrenia · United States1CompletedMar 15, 2022281
NCT04572685Schizophrenia Patients · United States1CompletedJun 26, 202036

How it is read

Names in the registry

  • “Paliperidone ER”, 39 entries
  • “Paliperidone”, 13 entries
  • “Paliperidone palmitate”, 10 entries
  • “paliperidone palmitate”, 7 entries
  • “Paliperidone Palmitate”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.